share_log

HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $600

HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $600

HC Wainwright & Co. 維持對福泰製藥的買入評級,將目標股價上調至600美元。
Benzinga ·  15:29  · 評級/大行評級

HC Wainwright & Co. analyst Andrew Fein maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $500 to $600.

HC Wainwright公司分析師Andrew Fein認爲福泰製藥(納斯達克: VRTX)值得買入且將價格目標從$500提高至$600。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論